Breast involvement by immunolymphoproliferative disorders is rare. Primary and secondary malignant lymphomas of the breast are much more common than multiple myeloma, of which only 16 cases have been described. We report two cases of patients with an established diagnosis of multiple myeloma in whom breast involvement appeared during the course of the disease. We underline diagnostic difficulties caused by the lack of clinical and radiological features which allow us to differentiate between breast carcinoma and breast involvement by lymphoproliferative disease. Only fine needle aspiration and/or excisional biopsy can differentiate between immunolymphoproliferative disorders and epithelial or mesenchymal tumors of the breast.
Introduction
Non-Hodgkin's lymphomas (NHL) and multiple myeloma (MM) are the most frequent lympho-immunoproliferative disorders, but their localization in the breast is quite rare.
MM is a disseminated malignant B-cell lineage neoplasm, characterized by clonal proliferation of plasma cells in the bone marrow, associated with the overproduction of structurally homogeneous immunoglobulins (M-component). They represent the most frequent form of plasma cell dyscrasias and about 1% of all types of tumors [1] . The incidence increases progressively with age and the mean age at diagnosis is about 65 years, while the onset in children [2] and young adults before 40 years is very rare [3] . Impaired hemopoiesis, renal failure, osteolytic bone lesions, recurrent infections, hypercalcemia are the most common features of the disease.
Clinically apparent extraosseous manifestation are present in less than 5% of patients with multiple myeloma and are usually associated with more aggressive behaviour, resistance to treatment and shorter survival.
Clinicopathologic studies, however, show extraosseous involvement in about two third of the patients, liver, spleen and lymph nodes being the most frequent sites [4, 5] . Central nervous system, kidney, skin, pleura, lung, testes, pancreas, thyroid, adrenal glands and omental involvement have also been described.
Few cases of breast multiple myeloma are reported in the literature [2, [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Ross et al. [15] described one case and reviewed 10 cases of multiple myeloma of the breast reported up to 1987. Furthermore, one case by Collins et al. [16] and two cases by Moulopoulos et al. [17] have been reported, the latter only as imaging features without any further information.
More recently two cases have been described by Kim [18] and Ariad [19] .
Primary NHL of the breast is much more common, representing from 0.04% to 0.53% of all malignant breast tumors [20, 21] and approximately 2.2% of all extranodal lymphomas [22] .
Secondary breast involvement by NHL is more frequent [23] than primary NHL, but the relative frequency of primary versus secondary NHL is quite variable in the various reports [24, 25] . The criteria for the diagnosis of primary breast NHL proposed by Wiseman and Liao include: 1) technically adequate specimens; 2) lymphomatous infiltration of mammary tissue; 3) no evidence of concurrent widespread disease and 4) no prior diagnosis of extramammary lymphoma [21] .
The mean age of onset of primary NHL of the breast is about 50-60 years [24] [25] [26] [27] , but in some cases lymphoma can arise even in younger patients. The most frequent histological subtypes arc entities in the intermediate and high-grade categories (F-H) in the WF classification [28] and they seem to represent about 80% of all the primary lymphoma of the breast. Burkitt-type lymphoma is generally correlated to bilateral diffuse disease in pregnant or lactating women.
In this report we describe the cases of two patients with established diagnosis of multiple myeloma treated with cytotoxic combination chemotherapy who developed breast involvement during the course of the disease. We discuss their initial management and that of NHL involving the breast. 
Case reports

Case 1
A 38-year-old woman was diagnosed as having IgD (X) MM, stage IIIA in 1992.
She was treated with alternating VAD/MP (vincristine, adriamycin, dexamethazone-melphalan, prednisone) chemotherapy for eight courses, and then underwent allogenic bone marrow transplantation using a histocompatible sibling donor.
The patient obtained a partial response of 10 months duration. Following progression of her disease she underwent high-dose melphalan chemotherapy followed by PBSC support, but no clinical response was obtained. The disease progressed and in September 1995 a palpable mass (2.2 x 2.0 cm) appeared in the upper-inner quadrant of the left breast.
Mammography showed the presence of a nodular mass measuring 2.2 x 1.7 cm with two further nodules which were clinically undetectable ( Figure 1) . Similarly, two clinically non palpable masses were present in the right breast.
Ultrasound examination using a 7.5 MHz linear array showed a disomogeneous echo poor solid mass with rather distinct margins with posterior reinforcement (Figure 2 ). Fine needle aspiration biopsy was performed and the smears revealed a population of immature nucleolated plasma cells ( Figure 3 ).
The patient refused to undergo excisional biopsy and died of acute renal failure in December 1995.
Case 2
A 53-year-old woman was diagnosed to have IgG (k) MM stage IIIA in 1993, and was treated with alternating cycles of VAD and MP for a total of eight courses, obtaining a disease stabilization. She refused high-dose chemotherapy with PBSC reinfusion and when the disease progressed was treated with cyclophosphamide 2000 mg i.v. every 28 days for 6 courses, but only a small decrease of her M-component was obtained.
In December 1996 the patient felt a mass in the left breast. At clinical examination there were two palpable nodules in the left (the larger 2.4 x 1.8 cm) and one in the right breast (2.2 x 2.0 cm).
Mammography showed multiple nodular masses bilaterally. In the left breast the largest nodules were in the upper-outer quadrant (2.2 x 1.6 cm) and in the medianinferior quadrant (2.0 x 1.7 cm) ( breast a mass measuring 2.2 x 2.0 cm was detected. Numerous solid nodules of different diameter from a few millimeters to 1.5 cm were evident bilaterally.
Ultrasound examination of the breast showed solid echo-poor masses with regular margins and posterior reinforcement ( Figure 5 ). Fine needle aspiration cytology showed immature nucleolated plasma cells.
Excisional biopsy was performed, histological examination confirming the myelomatous nature of the masses. Microscopically ( Figure 6 ) the nodules were composed of tightly packed immature plasma cells infiltrating the stroma.
Some residual lobular glands were evident focally throughout the neoplastic infiltration.
Immunohistochemistry revealed monotypical expres- sion of lambda light chains. The lymphoid markers CD20, CD79alfa and CD3 were negative. She was subsequently treated with VBAP (vincristine, BCNU, adriamycin, prednisone) combination chemotherapy for two cycles, but the disease progressed and she died from infectious complications in March 1997.
Discussion
Ductal and lobular carcinoma are the most frequent malignant disease of the breast, while lymphoproliferative disorders and mesenchymal tumors are exceedingly rare.
Patients affected by immunolymphoproliferative disorders, particularly when treated with chemotherapy, may develop secondary tumor in the breast. The appearance of breast nodules in patients with an immunoproliferative disorders make it mandatory to differentiate between primary breast cancer and a hematological malignancy.
Multiple myeloma is a systemic disease which may involve extraosseous sites, but only in rare occasions has it been found in the breast. To date, we have only found 16 case reports describing multiple myeloma involving the breast.
Five cases were solitary plasmocytomas [7, [10] [11] [12] [13] [14] , four were synchronous with the diagnosis of multiple myeloma [2, 8, 11, 19] , while in one case the breast tumor preceded the diagnosis [6] and in four patients the breast involvement followed an established diagnosis of multiple myeloma [9, 15, 16, 18] . Among these fourteen patients the distribution of the nodules was unilateral in nine patients and bilateral in five. In the remaining two cases in the literature no clinical information was available [17] . In both patients described in this paper breast lumps appeared during the course of aggressive multiple myeloma with circulating immunoglobulins, IgD and IgG, respectively, and the same lambda light-chain. In both patients breast involvement was bilateral and the only clinically evident site of extraosseous disease.
Analysis of data reported in the literature are consistent with a lack of clinical or instrumental features that allow us to differentiate between multiple myeloma involving the breast and breast carcinoma. In particular, mammography and ultrasound examination does not help the differential diagnosis. The mammographic pattern of multiple myeloma is generally characterized by round or lobulated well denned nodules mimicking a benign process without microcalcification.
Recently Collins et al. [16] described one case of breast multiple myeloma using ultrasound and color Doppler examination. The presence of an echo-poor mass with posterior acoustic shadowing and the presence of neovascularization was similar to those found in presence of carcinoma.
In our two cases the ultrasound images showed relatively echo-poor masses with rather distinct margins and posterior reinforcement. The mammographic pattern was that of nodules with well-defined margins without parenchymal distorsion and/or calcification.
Similarly there are no features at presentation that can distinguish patients with breast involvement by NHL from those with benign or malignant tumors of the breast. The mean age at the onset of breast lymphoma and carcinoma is identical [24] . Clinically, primary breast NHL is generally larger than breast carcinoma at diagnosis (41% of primary breast NHL have a diameter between 4.5 and 7.5 cm) [27] and they are found more frequently in the right breast, while bilateral involvement by NHL is present in only 5% of the patients [21, 24, 25] .
The low incidence and the lack of specific clinical and radiological characteristics make a preoperatory diagnosis very difficult. The mammographic pattern of the most primary NHL is of round/oval or lobulated nodules (sometimes with minimal or moderate spiculation). These are quite well circumscribed and can mimic a benign process, especially in patients younger than 35 years when the breast parenchyma may be quite dense and the margins are not well seen [29] .
Marginal spiculation is in contrast easier to show in the fatty breast of older women.
In some cases the mammographic pattern is similar to carcinoma without the presence of microcalcification or parenchymal distortion [29, 30] . Secondary involvement of the breast by NHL is often bilateral. The mammographic picture is generally characterized by increase in parenchymal density and skin thickening, as in inflammatory breast carcinoma [31] . Ultrasound examination generally reveals hypoechoic rounded masses without distal attenuation [32] . Primary NHL of the breast are often divided into a 'unilateral' type, which mimics breast carcinoma in age distribution and which accounts for 84% of the cases reported in the literature, and a 'bilateral diffuse' type. This second type affects pregnant or lactating women and is characterized by rapid growth followed by widespread dissemination with prominent ovarian and CNS involvement and histologically is a Burkitt-like lymphoma [33, 34] .
The most frequent histological type is diffuse largecell NHL, in both primary and secondary breast involvement [21, 27, 35] , while low-grade lymphomas are generally rare. The vast majority of tumors are of B-cell origin and this is consistent with the onset in the mucosaassociated lymphoid tissue (MALT) [36] .
Many reports [35] [36] [37] [38] consider intraepithelial lymphocytes of the breast to be an example of MALT. The relative rarity of breast lymphomas compared with those arising in the gut or lung is explained by the paucity of lymphoid tissue in the breast [39] . Some cases of lowgrade lymphomas and low-grade components in B-cell high-grade lymphomas of the breast seem to suggest an origin of breast NHL from MALT, though not all the authors [19, 40] concur and consider that the vast majority of breast NHL differ from other extranodal lymphomas and do not have the features of MALT lymphomas.
B-cell follicular [20, 38] and high-grade T-cell lymphomas [19, 24, 25] are rarely diagnosed.
In the presence of primary or secondary involvement of the breast by lymphoproliferative disease, mammography and ultrasound examination can identify and morphologically characterize the lesion(s), but do not reveal the diagnosis. Only fine needle aspiration cytology and/or excisional biopsy can differentiate NHL or MM involvement of the breast from epithelial tumors or other benign or malignant breast masses. Although primary or secondary breast involvement with NHL or MM is rare, when one or more nodules are recognized it is helpful to consider the possibility of breast involvement by an immunolymphoproliferative disorder. Fine needle aspiration and/or surgical biopsy is mandatory for the correct diagnosis and treatment of the disease.
Plasma cells tumors may appear either in a solitary form or as disseminated multiple myeloma. Extramedullary plasmocytomas are rare and can represent either the initial manifestation of systemic MM or remain solitary for long time. Among the five patients with solitary breast plasmocytoma in two cases the localization was bilateral [7, 12] , whereas in the other three it appeared to be a 'true' solitary plasmocytoma [10, 13, 14] . Only in one case was the breast involvement associated with a serum monoclonal gammopathy which disappeared after local treatment [14] .
In all the three cases no recurrence has been shown after 40 months [14] , 46 months [10] and 9 years [13] at the time of pubblication. The usual treatment of extramedullary plasmocytoma is radiotherapy with excellent long time results. The treatment of solitary plasmocytoma of the breast should consist of local excision followed by radiation therapy, whereas when breast involvement is secondary to disseminated MM the treatment should be that of the basic disease employing the most widely used polichemotherapy schedules like VAD (vincristine, adriamycine, dexamethazone) or MP (melphalan, 6-methilprednisolone).
The natural history of primary NHL of the breast seems to be quite different from lymphomas of other extranodal sites because of its rapid progression and worse prognosis [19, 21] .
The progression of the disease more frequently occurs in lymph nodes and skin whereas liver, spleen, bone, ovaries and lung are seldom involved [27, 41, 42] . Tumor size, stage according to Ann Arbor staging system and histologic characteristics seem to affect the prognosis.
Large tumor size appears to worsen the probability of survival in some reports [26, 31] ), but not in other [25, 43] , as well as patients with stage IE disease have a better outcome compared with stage HE [31, [43] [44] [45] . Five years median survival is widely variable between 16% and 85% [20, 27, 31, 41, 42] and appears higher in low-grade NHL [27, 31, 41, 46] . Dixon et al. reported a 5-and 10-year overall survival of 85% and 73%, respectively, in 14 patients treated with a combination of surgery, radiotherapy and chemotherapy [31] .
In a study conducted at the Italian National Cancer Institute of Milan in 32 patients, five-year overall survival rate was 61% in stage I disease and 27% in stage II, whereas freedom from progression at five year was 50% for stage I and 26% for stage II disease [43] .
In a recent study on 23 patients followed at the M.D. Anderson Cancer Center the five-year survival and RFS were 74% and 73%, respectively, for all the patients and 65% and 70%, respectively, for diffuse large-cell histologic subtype [45] .
There is no general agreement on the appropriate treatment of NHL of the breast and the therapeutic approach remains controversal for the relative rarity of the disease and the lack of multicentric randomized studies.
Excisional biopsy plus radiation therapy has been the most widely used therapeutic strategy in small stage IE primary lymphomas of the breast [31, 47] , whereas in the presence of larger tumors, of axillary lymph node involvement (stage HE), or of high grade histologic subtype, combination chemotherapy with or without local irradiation seems to be the most appropriate treatment modality [19, 31, 43, 45, 48] . The results reported in the most recent studies support the impression that with modern staging evaluation and multidrug combination chemotherapy (mainly anthracycline containing regimens) associated or not with radiotherapy, the prognosis of primary NHL of the breast should be similar to that of equivalent types of lymphoma occurring in the other nodal and extranodal sites.
